Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model

被引:30
|
作者
Vollherbst, Dominik F. [1 ,2 ]
Otto, Ruth [1 ]
von Deimling, Andreas [3 ,4 ]
Pfaff, Johannes [1 ]
Ulfert, Christian [1 ]
Kauczor, Hans U. [2 ]
Bendszus, Martin [1 ]
Sommer, Christof M. [2 ,5 ]
Moehlenbruch, Markus A. [1 ]
机构
[1] Univ Hosp Heidelberg, Dept Neuroradiol, INF 400, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Dept Diagnost & Intervent Radiol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Dept Neuropathol, CCU Neuropathol, DKTK, Heidelberg, Germany
[4] DKFZ, Heidelberg, Germany
[5] Klinikum Stuttgart, Clin Diagnost & Intervent Radiol, Stuttgart, Germany
关键词
arteriovenous malformation; liquid embolic material; intervention; BRAIN ARTERIOVENOUS-MALFORMATIONS; SWINE RETE-MIRABILE; PRELIMINARY EXPERIENCE; ORGANIC-SOLVENTS; ONYX; FEASIBILITY; MULTICENTER;
D O I
10.1136/neurintsurg-2017-013144
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background The choice of the embolic agent and the embolization technique can have a significant impact on the success of endovascular embolization. Objective To evaluate a novel iodinated copolymer-based liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in the porcine rete mirabile (RM), serving as an endovascular embolization model. Onyx, as an established liquid embolic agent, served as comparator. Materials and methods Sixteen embolization procedures were performed using PHIL (n=8) or Onyx (n=8) as liquid embolic agent. Waiting time between injections was set to 30 or 60s (n=4 per study group). Survival time after intervention was 2hours or 7 days. Embolization characteristics (eg, procedure times, number of injections and volume of embolic agent) and embolization extent (percentage of embolized RM in post-interventional x-ray) were assessed. Post-interventional CT and histopathological analyses were performed. Results Embolization characteristics and embolization extent were not significantly different for PHIL and Onyx, including subgroups (eg, embolization extent 44% vs 69% (medians); p=0.101). For PHIL, extension of the waiting time from 30 to 60s led to a significantly higher embolization extent (24% vs 72% (medians); p=0.035). Moderate disintegration and mild inflammation of the embolized blood vessels were present for both embolic agents. Conclusion PHIL is feasible for transarterial embolization in an acute and subacute endovascular embolization model. In this preliminary experimental in vivo study, embolization characteristics, embolization extent, and biocompatibility seem to be similar to those of Onyx.
引用
收藏
页码:268 / 274
页数:7
相关论文
共 50 条
  • [1] Endovascular embolization of canine hepatic arteriovenous malformations using precipitating hydrophobic injectable liquid (PHIL) liquid embolic agent: a proof of concept study
    Ryan, Stewart D.
    Nambiar, Anjali
    Maingard, Julian
    Kok, Hong Kuan
    Turner, Robert B. S.
    Brooks, Duncan Mark
    Asadi, Hamed
    CVIR ENDOVASCULAR, 2019, 2 (01)
  • [2] Endovascular embolization of canine hepatic arteriovenous malformations using precipitating hydrophobic injectable liquid (PHIL) liquid embolic agent: a proof of concept study
    Stewart D. Ryan
    Anjali Nambiar
    Julian Maingard
    Hong Kuan Kok
    Robert B. S. Turner
    Duncan Mark Brooks
    Hamed Asadi
    CVIR Endovascular, 2
  • [3] Liquid Embolic Agents for Endovascular Embolization: Evaluation of an Established (Onyx) and a Novel (PHIL) Embolic Agent in an In Vitro AVM Model
    Vollherbst, D. F.
    Sommer, C. M.
    Ulfert, C.
    Pfaff, J.
    Bendszus, M.
    Moehlenbruch, M. A.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2017, 38 (07) : 1377 - 1382
  • [4] Introducing PHIL (precipitating hydrophobic injectable liquid) - a new embolic agent for the body interventional radiologist
    Prashar, Akash
    Butt, Saqib
    Shaida, Nadeem
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2020, 26 (02) : 140 - 142
  • [5] Treatment of Type II Endoleaks with a Novel Agent: Precipitating Hydrophobic Injectable Liquid (PHIL)
    Amir Helmy
    Nadeem Shaida
    CardioVascular and Interventional Radiology, 2017, 40 : 1094 - 1098
  • [6] Treatment of Type II Endoleaks with a Novel Agent: Precipitating Hydrophobic Injectable Liquid (PHIL)
    Helmy, Amir
    Shaida, Nadeem
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (07) : 1094 - 1098
  • [7] Embolization of peripheral arteriovenous malformations and fistulas with precipitating hydrophobic injectable liquid (PHIL®)
    Francesco Giurazza
    Fabio Corvino
    Mattia Silvestre
    Gianluca Cangiano
    Giuseppe De Magistris
    Errico Cavaglià
    Francesco Amodio
    Raffaella Niola
    La radiologia medica, 2021, 126 : 474 - 483
  • [8] Embolization of peripheral arteriovenous malformations and fistulas with precipitating hydrophobic injectable liquid (PHIL(R))
    Giurazza, Francesco
    Corvino, Fabio
    Silvestre, Mattia
    Cangiano, Gianluca
    De Magistris, Giuseppe
    Cavaglia, Errico
    Amodio, Francesco
    Niola, Raffaella
    RADIOLOGIA MEDICA, 2021, 126 (03): : 474 - 483
  • [9] Precipitating hydrophobic injectable liquid (PHIL) embolic for the treatment of a uterine arteriovenous malformation: a technical report
    Kurda, Dylan
    Guduguntla, Geetha
    Maingard, Julian
    Kok, Hong Kuan
    Lalloo, Shivendra
    CVIR ENDOVASCULAR, 2019, 2 (01)
  • [10] Precipitating hydrophobic injectable liquid (PHIL) embolic for the treatment of a uterine arteriovenous malformation: a technical report
    Dylan Kurda
    Geetha Guduguntla
    Julian Maingard
    Hong Kuan Kok
    Shivendra Lalloo
    CVIR Endovascular, 2